USA flag logo/image

An Official Website of the United States Government

Lab-on-a-chip for Neonatal Hyperbilirubinemia Screening

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93905
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
HD062316
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADVANCED LIQUID LOGIC
615 Davis Dr., Suite 800 PO Box 14025 RESEARCH TRIANGLE PARK, NC -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Lab-on-a-chip for Neonatal Hyperbilirubinemia Screening
Agency: HHS
Contract: 1R43HD062316-01
Award Amount: $189,378.00
 

Abstract:

DESCRIPTION (provided by applicant): Despite aggressive public health campaigning and strict guidelines for diagnosis and treatment, the estimated incidence of severe hyperbilirubinemia (defined as serum bilirubin levels greater than 99th percentile) is 1: 70. Severe hyperbilirubinemia can cause a spectrum of neurologic dysfunction of which kernicterus is the most concerning. Kernicterus manifests as a life-long movement disorder with occulomotor and auditory dysfunction. The subcommittee on Hyperbilirubinem ia of the American Academy of Pediatrics (AAP) has proposed guidelines to reduce the frequency of severe neonatal hyperbilirubinemia and bilirubin encephalopathy. These include the recommendation to measure total serum bilirubin level or cutaneous bilirubi n level of all infants with jaundice in the first 24 hours of life. The committee also identified the need for screening for hereditary causes such as G6PD deficiency and congenital hypothyroidism, which if present can change the treatment completely. Earl y identification and initiation of treatment can prevent acute bilirubin encephalopathy and kernicterus. Currently testing for hyperbilirubinemia is often available at the point of care, but results are usually returned after patient discharge. Tests for G 6PD and CH are usually done only if the patient does not respond to therapy. In this proposal, we describe a new technology that has the potential to dramatically simplify the testing process and expedite the availability of test results. Time is of the es sence in diagnosis of these newborn conditions as significant brain injury can be prevented by prompt treatment. This new technology will require minimal resources, will be low cost, and will be suitable for use in hospitals, outpatient clinics, and rural communities. Availability of portable and multiplex devices for on-site screening will enable rapid diagnosis of at-risk infants. Development of a device that could perform multiple assays for common newborn disorders at the point-of-care with rapid turnar ound is an initial step in the development of multiplex testing with an on-site portable device. PUBLIC HEALTH RELEVANCE: Advanced Liquid Logic, Inc. is developing a lab-on-a-chip on its proprietary digital (droplet-based) microfluidic platform for clinica l diagnostics. The proposed project aims to demonstrate a near-patient platform for screening neonates with very high levels of bilirubin (hyperbilirubinemia). The device would be greatly useful in rapid identification and enable early treatment.

Principal Investigator:

Vijay Srinivasan

Business Contact:

Richard M. West
information@liquid-logic.com
Small Business Information at Submission:

ADVANCED LIQUID LOGIC
ADVANCED LIQUID LOGIC 615 Davis Dr., Suite 800 RESEARCH TRIANGLE PARK, NC 27709

EIN/Tax ID: 201708967
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No